The translational therapeutics of prostaglandin inhibition in atherothrombosis.
Prostaglandins, products of the cyclo-oxygenase (COX) enzymes, can both promote and restrain atherothrombosis. While non-steroidal anti-inflammatory drugs (NSAIDs) selective for inhibition of COX-2 predispose to myocardial infarction, heart failure, hypertension and stroke, suppression of products of COX-1, such as thromboxane (Tx) A2, underlie cardioprotection from low-dose aspirin. Data from clinical pharmacology, rodent models, human genetics, observational studies and randomized trials provide insight into the implications of inhibiting COX product synthesis or function. Many lines of evidence afford a mechanistic explanation for the cardiovascular (CV) hazard from NSAIDs. Elucidation of the biology of this pathway using diversified approaches is also relevant to understanding the implications of substrate rediversion following inhibition of enzymes downstream of COXs, such as the microsomal PGE synthase (mPGES)-1 and of combining D prostanoid antagonism with niacin to attenuate facial flushing.
Yu
Y
Y
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6084, USA.
Ricciotti
E
E
Grosser
T
T
Fitzgerald
G A
GA
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D011448:Prostaglandin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011448:Prostaglandin Antagonists